- Companies
- OpGen
OpGen Valuation Multiples
OpGen is valued at $49M as of October 2026, a 1.7x revenue multiple. In the last fiscal year, OpGen revenue was $30M and OpGen EBITDA was $24M.
OpGen Overview
About OpGen
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Founded
2001
HQ
Employees
4
Website
Financials (Last FY)
EV
$51M
Valuation Multiples
Start free trialOpGen Financials
OpGen reported last fiscal year revenue of $30M and EBITDA of $24M.
In the same fiscal year, OpGen generated $27M in gross profit, $24M in EBITDA, and $24M in net income.
OpGen P&L
In the most recent fiscal year, OpGen reported revenue of $30M and EBITDA of $24M.
OpGen is profitable as of last fiscal year, with gross margin of 90%, EBITDA margin of 80%, and net margin of 78%.
Financial data powered by Morningstar, Inc.
OpGen Stock Performance
OpGen has current market cap of $49M, and enterprise value of $51M.
Market Cap Evolution
OpGen's stock price is $3.96.
OpGen share price decreased by 1.9% in the last 30 days, and increased by 1981753.1% in the last year.
OpGen has an EPS (earnings per share) of $1.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51M | $49M | -0.8% | -1.9% | -56.7% | 1981753.1% | $1.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOpGen Valuation Multiples
OpGen trades at 1.7x EV/Revenue multiple, and 2.1x EV/EBITDA.
OpGen Financial Valuation Multiples
As of October 14, 2026, OpGen has market cap of $49M and EV of $51M.
OpGen has a P/E ratio of 2.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OpGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


OpGen Margins & Growth Rates
In the most recent fiscal year, OpGen reported gross margin of 90%, EBITDA margin of 80%, and net margin of 78%.
OpGen Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
OpGen Operational KPIs
OpGen's revenue per employee in the last FY averaged $7.5M, while opex per employee averaged $1.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
OpGen Competitors
OpGen competitors include EDX Medical Group, Atlantic International, Cryosite, Pangaea Oncology, Abingdon Health, iNtRON Biotechnology, Lumos Diagnostics Hldgs, Osang Healthcare, Cleo Diagnostics and IMBdx.
Most OpGen public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $438K | ($7M) | 89.3x | - | (5.3x) | - | |||
| $436M | ($44M) | 1.4x | 1.4x | (13.7x) | - | |||
| $12M | $3M | 3.8x | - | 15.0x | - | |||
| $16M | ($1M) | 3.8x | 3.6x | (58.0x) | (19.3x) | |||
| $11M | ($4M) | 2.9x | 2.1x | (8.4x) | (20.9x) | |||
| $4M | ($6M) | 9.1x | - | (6.7x) | - | |||
| $13M | ($412K) | 4.0x | 3.4x | (129.6x) | (9.4x) | |||
| $96M | $8M | 0.7x | - | 7.9x | - | |||
This data is available for Pro users. Sign up to see all OpGen competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by OpGen
OpGen has acquired 1 company to date.
Last acquisition by OpGen was on July 14th 2015. OpGen acquired AdvanDx for undisclosed valuation.
Latest Acquisitions by OpGen
| Description | AdvanDx is a Woburn, Massachusetts-headquartered provider of molecular diagnostics for infectious diseases in hospitals. The company offers FDA-cleared assays like SeptiFast for sepsis pathogens and EasyMAG for nucleic acid extraction. Founded in 2002, it serves over 500 laboratories in Europe and North America with automated PCR workflows. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 14 Jul 2015 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all OpGen acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OpGen
| When was OpGen founded? | OpGen was founded in 2001. |
| Where is OpGen headquartered? | OpGen is headquartered in United States. |
| How many employees does OpGen have? | As of today, OpGen has over 4 employees. |
| Is OpGen publicly listed? | Yes, OpGen is a public company listed on OTCM. |
| What is the stock symbol of OpGen? | OpGen trades under CFOR ticker. |
| When did OpGen go public? | OpGen went public in 2015. |
| Who are competitors of OpGen? | OpGen main competitors include EDX Medical Group, Atlantic International, Cryosite, Pangaea Oncology, Abingdon Health, iNtRON Biotechnology, Lumos Diagnostics Hldgs, Osang Healthcare, Cleo Diagnostics, IMBdx. |
| What is the current market cap of OpGen? | OpGen's current market cap is $49M. |
| What is the current revenue of OpGen? | OpGen's last fiscal year revenue is $30M. |
| What is the current EV/Revenue multiple of OpGen? | Current revenue multiple of OpGen is 1.7x. |
| Is OpGen profitable? | No, OpGen is not profitable. |
| How many companies OpGen has acquired to date? | As of October 2026, OpGen has acquired 1 company. |
| What was the largest acquisition by OpGen? | None of the M&A deals OpGen has completed have disclosed valuations. |
| What companies OpGen acquired? | OpGen acquired AdvanDx. |
| In how many companies OpGen has invested to date? | OpGen hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to OpGen
Lists including OpGen
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




